# Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenègre,Bartomeu Massutí,Enriqueta Felip,Ramón Palmero,Ramón García-Gómez,Cinta Pallarés,José Miguel Sánchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Morán,Amelia Insa,Filippo de Marinis,R. Corre,Isabel Bover,Alfonso Illiano,Éric Dansin,Javier de Castro,Michèle Milella,Noemı́ Reguart,Giuseppe Altavilla,Ulpiano Jiménez,Mariano Provencio,Miguel Ángel Moreno,Josefa Terrasa,José Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Dómine,Olivier Molinier,Julien Mazières,Nathalie Baize,Rosario García‐Campelo,G. Robinet,Delvys Rodríguez‐Abreu,Guillermo López-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,P. Bombaron,Reyes Bernabé,Alessandra Bearz,Á. Artal,Enrico Cortesi,Christian Rolfo,María Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,José Luis Ramírez,José Javier Sánchez,Miguel Ángel Molina‐Vila,Miquel Tarón,Luis Paz‐Ares |
| Citations | 5,545 |
| DOI | 10.1016/s1470-2045(11)70393-x |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | http://hdl.handle.net/20.500.11940/7760 |
| OpenAlex ID | https://openalex.org/W2111662961 |
| PMID | 22285168 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Julien Mazières](https://scholariq.org/researchers/julien-mazieres/)
- [Enriqueta Felip](https://scholariq.org/researchers/enriqueta-felip/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.